TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33034159

Group type: EXPERIMENTAL
Intervention: CASS with interested confederates
Number of subjects: 50

Group type: COMPARATOR
Intervention: CASS with bored confederates
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CASS social behavior and social cognition tasks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CASS social behavior
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CASS
Number of subjects: 50
Study: 32439482

Group type: EXPERIMENTAL
Intervention: 5-day azithromycin (AZM) only (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Scaling and prescribed AZM after 2 months (n=12)
Number of subjects: 24
Study: 35150170

Group type: EXPERIMENTAL
Intervention: Immediate loading (placement of permanent prosthesis within 7 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Delayed loading (placement of permanent prosthesis after 3 months)
Number of subjects: 41
Study: 33909052

Group type: EXPERIMENTAL
Intervention: Informed consent documents from COVID-19 vaccine trials
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Improved informed consent document
Number of subjects: 4
Study: 33938260

Group type: EXPERIMENTAL
Intervention: 1-year extension of early intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Step-down psychiatric care
Number of subjects: 160
Study: 32591433

Group type: EXPERIMENTAL
Intervention: ChAdOx1-MVA 5T4 vaccine
Number of subjects: 40
Study: 33078646

Group type: EXPERIMENTAL
Intervention: Multi-vitamin-mineral supplement (MVMS)
Number of subjects: 54
Study: 34401514

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 80

Group type: COMPARATOR
Intervention: Semont maneuver
Number of subjects: 80
Study: 32538835

Group type: EXPERIMENTAL
Intervention: Increased serum calcium level (per 1 standard deviation (SD) increase 0.5 mg/dL)
Number of subjects: 54062
Study: 34271963

Group type: EXPERIMENTAL
Intervention: Single-agent oral selinexor
Number of subjects: 100
Study: 32535481

Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot (AM) 2.5 g three times per day for 48 weeks
Number of subjects: 1470

Group type: COMPARATOR
Intervention: losartan potassium 100 mg per day for 48 weeks
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot (AM)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: losartan potassium
Number of subjects: 1470
Study: 35460807

Group type: EXPERIMENTAL
Intervention: VR exergaming during cycling
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard exercise (without VR)
Number of subjects: 34
Study: 33931254

Group type: EXPERIMENTAL
Intervention: Listening to podcasts while driving
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sitting undistracted while listening to podcasts
Number of subjects: 100
Study: 35919945

Group type: EXPERIMENTAL
Intervention: Upadacitinib monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib plus csDMARD therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: csDMARD-only therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: bDMARD plus csDMARD therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0
Study: 33257661

Group type: EXPERIMENTAL
Intervention: 10-mg oral methotrexate once weekly with daily 5-mg folic acid for 12 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Matching placebo with daily 5-mg folic acid for 12 weeks
Number of subjects: 92
Study: 37225870

Group type: COMPARATOR
Intervention: Conventional irrigation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sonic irrigation activation system
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Irradiation with a 980 nm diode laser and conventional irrigation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Irradiation with a 980 nm diode laser and sonic irrigation activation system
Number of subjects: 80
Study: 33588596

Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Edaravone
Number of subjects: 1165
Study: 35985457

Group type: COMPARATOR
Intervention: 74 Gy/37 fractions (Fr)
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: 60 Gy/20 Fr
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: 57 Gy/19 Fr
Number of subjects: 3216
Study: 32578778

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral nerve block (TPVB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasound-guided intercostal nerve block (ICNB)
Number of subjects: 100
Study: 35114353

Group type: EXPERIMENTAL
Intervention: Outpatient integrated palliative care
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 210
Study: 34107180

Group type: EXPERIMENTAL
Intervention: wMel-infected Aedes aegypti mosquito deployments (intervention clusters)
Number of subjects: 8144

Group type: COMPARATOR
Intervention: No deployments (control clusters)
Number of subjects: 8144
Study: 35248681

Group type: EXPERIMENTAL
Intervention: Tailored postal reminder intervention (showing information on the nearest clinic from each participant's address)
Number of subjects: 21017

Group type: COMPARATOR
Intervention: Standard postal reminder (containing just the URL of the website listing all available clinics)
Number of subjects: 21017

Group type: EXPERIMENTAL
Intervention: Tailored postal reminder intervention
Number of subjects: 21017
Study: 32139496

Group type: EXPERIMENTAL
Intervention: Nurse-delivered sleep restriction therapy (SRT) plus sleep hygiene booklet
Number of subjects: 588

Group type: COMPARATOR
Intervention: Sleep hygiene booklet on its own
Number of subjects: 588
Study: 33556413

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day (n = 32)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard therapy (n = 19)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day (n = 32) in statin non-users
Number of subjects: 51
Study: 33084475

Group type: EXPERIMENTAL
Intervention: Modified Lifespan Integration (MLI) - one session of 90-140 minutes
Number of subjects: 38
Study: 34195214

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulses plus tacrolimus and standard of care (SoC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 55
Study: 35184326

Group type: EXPERIMENTAL
Intervention: Low-dose aripiprazole adjunctive to antidepressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34024791

Group type: EXPERIMENTAL
Intervention: Active high frequency navigated perilesional rTMS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham high frequency navigated perilesional rTMS
Number of subjects: 32
Study: 35429381

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 380
Study: 34057625

Group type: EXPERIMENTAL
Intervention: Bioabsorbable mesh plus continuous polydioxanone suture (PDS)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Continuous PDS single layer suture only
Number of subjects: 332
Study: 33429750

Group type: EXPERIMENTAL
Intervention: Bosentan combined with vardenafil oral group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vardenafil oral group
Number of subjects: 0
Study: 35611684

Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion sustained release for emotional hunger phenotype
Number of subjects: 0
Study: 36272432

Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg orally, twice daily for 5 days)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 180
Study: 34399982

Group type: EXPERIMENTAL
Intervention: Oral sodium nitrate (700 mg×2)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 82
Study: 32909657

Group type: EXPERIMENTAL
Intervention: Nicotine Dependence (ND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADHD
Number of subjects: 0
Study: 34183792

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33139276

Group type: EXPERIMENTAL
Intervention: Tribendimidine plus ivermectin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Tribendimidine monotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Tribendimidine plus oxantel pamoate
Number of subjects: 54
Study: 33326471

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study: 33966011

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 12
Study: 33232172

Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate (MPH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (lactose pill)
Number of subjects: 12
Study: 33075067

Group type: EXPERIMENTAL
Intervention: Intensive MDA (quarterly single-dose praziquantel 40mg/kg; triple-dose albendazole 400mg)
Number of subjects: 13382

Group type: COMPARATOR
Intervention: Standard Uganda government intervention (annual single-dose praziquantel 40mg/kg; 6-monthly single-dose albendazole)
Number of subjects: 13382
Study: 35905412

Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) with diet/exercise counseling for 32 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Counseling alone (control)
Number of subjects: 12
Study: 34170206

Group type: EXPERIMENTAL
Intervention: Side camera perspective
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Foot camera perspective
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Head camera perspective
Number of subjects: 93

Group type: COMPARATOR
Intervention: All camera perspectives
Number of subjects: 93
Study: 32233187

Group type: EXPERIMENTAL
Intervention: Gingival Unit Graft (GUG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free Gingival Graft (FGG)
Number of subjects: 30
Study: 34086129

Group type: EXPERIMENTAL
Intervention: Inconsistent risk messages from public health experts and elected officials
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Degree of infectiousness of the coronavirus
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Distrust of vaccine safety and general vaccine avoidance
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Severity of COVID-19
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Overall intention to vaccinate
Number of subjects: 3133
Study: 34343772

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic myomectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2D laparoscopic myomectomy
Number of subjects: 64
Study: 34086597

Group type: EXPERIMENTAL
Intervention: Linked Colour Imaging (LCI)
Number of subjects: 332

Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy (HD-WLE)
Number of subjects: 332
Study: 34703176

Group type: EXPERIMENTAL
Intervention: High scrotal approach
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 94
Study: 32433405

Group type: EXPERIMENTAL
Intervention: Robotic pancreaticoduodenectomy (RPD)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (OPD)
Number of subjects: 156
Study: 36204954

Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite composite material
Number of subjects: 72

Group type: COMPARATOR
Intervention: hydroxyapatite composite material
Number of subjects: 72
Study: 34085472

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture combined with row‐like puncture at sternocleidomastoid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study: 34843355

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Relaxation Therapy (RT)
Number of subjects: 86
Study: 35853676

Group type: EXPERIMENTAL
Intervention: Motivational counselling and text message reminders
Number of subjects: 150
Study: 36606011

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 70
Study: 32085633

Group type: EXPERIMENTAL
Intervention: Birch pollen immunotherapy
Number of subjects: 8
Study: 34966141

Group type: EXPERIMENTAL
Intervention: Azithromycin at 10 mg/kg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline at 4.4 mg/kg/d for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study: 35732989

Group type: EXPERIMENTAL
Intervention: hBO‐HD (640 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: hBO‐MD (320 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: hBO‐LD (160 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 33772435

Group type: EXPERIMENTAL
Intervention: Culturally adapted MREAL curriculum
Number of subjects: 5523

Group type: COMPARATOR
Intervention: Original kiREAL curriculum (translated into Spanish)
Number of subjects: 5523

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 5523
Study: 32594789

Group type: EXPERIMENTAL
Intervention: Mindfulness training plus moderate-to-vigorous intensity exercise
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity exercise alone
Number of subjects: 585

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 585
Study: 35270582

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT) for 10 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enhanced PFMT using EMG biofeedback for 10 weeks
Number of subjects: 60
Study: 34765004

Group type: EXPERIMENTAL
Intervention: High-sensitivity group (HSG) - acupressure at five acupoints with highest sensitivity to pain
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low-sensitivity group (LSG) - acupressure at five acupoints with lowest sensitivity to pain
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: High-sensitivity group (HSG)
Number of subjects: 202
Study: 33031293

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasound therapy
Number of subjects: 100
Study: 36239756

Group type: EXPERIMENTAL
Intervention: Sequential therapy with once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks
Number of subjects: 505

Group type: COMPARATOR
Intervention: Monotherapy with alendronate for 120 weeks
Number of subjects: 505
Study: 32789966

Group type: EXPERIMENTAL
Intervention: Raltitrexed (RTX) 2 mg/m2 every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raltitrexed (RTX) 3 mg/m2 every 3 weeks
Number of subjects: 0
Study: 32511687

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg by intravenous infusion every 24 weeks)
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Interferon β‐1a (44 μg subcutaneously 3 times a week)
Number of subjects: 1656

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Interferon β‐1a
Number of subjects: 1656
Study: 35248721

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 35045390

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for younger patients
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for older patients
Number of subjects: 356

Group type: COMPARATOR
Intervention: No-age control group
Number of subjects: 356
Study: 33599430

Group type: EXPERIMENTAL
Intervention: Dietary habits assessment of male adolescents with type 1 diabetes
Number of subjects: 20
Study: 32152817

Group type: EXPERIMENTAL
Intervention: Group-based education (GE)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Social network-based education (SNE)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (routine lymphedema treatments)
Number of subjects: 105
Study: 35512728

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 14221

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14221

Group type: EXPERIMENTAL
Intervention: Remdesivir (ventilated patients)
Number of subjects: 14221

Group type: COMPARATOR
Intervention: Control (ventilated patients)
Number of subjects: 14221

Group type: EXPERIMENTAL
Intervention: Remdesivir (not ventilated but on oxygen)
Number of subjects: 14221

Group type: COMPARATOR
Intervention: Control (not ventilated but on oxygen)
Number of subjects: 14221

Group type: EXPERIMENTAL
Intervention: Remdesivir (not on oxygen initially)
Number of subjects: 14221

Group type: COMPARATOR
Intervention: Control (not on oxygen initially)
Number of subjects: 14221

Group type: EXPERIMENTAL
Intervention: Remdesivir (all not ventilated initially)
Number of subjects: 14221

Group type: COMPARATOR
Intervention: Control (all not ventilated initially)
Number of subjects: 14221
Study: 33858397

Group type: EXPERIMENTAL
Intervention: Physical activity (measured in MET∙h/day)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Hemoglobin concentration (g/dL)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI: kg/m2)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 330
Study: 36476247

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study: 33428786

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses) after preoperative systemic chemotherapy and surgical procedure.
Number of subjects: 25
Study: 34269818

Group type: EXPERIMENTAL
Intervention: Daratumumab/lenalidomide/dexamethasone (D‐Rd)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Daratumumab/bortezomib/melphalan/prednisone (D‐VMP)
Number of subjects: 718
Study: 33155417

Group type: EXPERIMENTAL
Intervention: Drug treatment (specific drug not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Censoring at initiation of subsequent therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Considering recurrence or progression events (including death) before and after initiation of subsequent therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Considering the start of subsequent therapy as an event
Number of subjects: 0
Study: 35762832

Group type: EXPERIMENTAL
Intervention: Patient-facing intervention using electronic health record functionalities (EHR)
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Secure messaging to eligible patients
Number of subjects: 1825

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 1825
Study: 34341153

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (incoBoNT/A)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 32618265

Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA) with dihydroartemisinin‐piperaquine (DHAP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Focal MDA with DHAP at the household level
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving standard of care
Number of subjects: 60
Study: 35108380

Group type: EXPERIMENTAL
Intervention: MDHAQ
Number of subjects: 13391
Study: 34274304

Group type: EXPERIMENTAL
Intervention: No intake of ASBs (intervention group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular intake of ASBs (control group)
Number of subjects: 45
Study: 35322232

Group type: COMPARATOR
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 33176712

Group type: EXPERIMENTAL
Intervention: Person-centred care
Number of subjects: 4831
Study: 33340154

Group type: EXPERIMENTAL
Intervention: Medical grade honey gel (L-Mesitran Soft®) applied intraoperatively on the linea alba
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no medical grade honey gel)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Medical grade honey gel (L-Mesitran Soft®)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Risk factors associated with infection
Number of subjects: 89
Study: 35792299

Group type: EXPERIMENTAL
Intervention: Affective Control Training (AffeCT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 48
Study: 34547261

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg tablet dissolved in apple juice)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (10 mL of apple juice)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33849611

Group type: EXPERIMENTAL
Intervention: InterFACE mHealth tool
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional communication methods
Number of subjects: 48
Study: 32495671

Group type: EXPERIMENTAL
Intervention: Position management, manual rotation of fetal position, use of a U‐shaped birth stool
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (position selected by women and routine nursing)
Number of subjects: 384
Study: 34614288

Group type: EXPERIMENTAL
Intervention: Interscalene block (Group-IB, n=20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: General anaesthesia (Group-GA, n=22)
Number of subjects: 42
Study: 34474682

Group type: EXPERIMENTAL
Intervention: Care manager model
Number of subjects: 9
Study: 32028255

Group type: EXPERIMENTAL
Intervention: Natural turf
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Astroturf
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Third-generation artificial turf
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GPS location at C7
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GPS location at mid-tibia
Number of subjects: 15
Study: 34301217

Group type: EXPERIMENTAL
Intervention: Hand-mixed GIC (Fuji IX®, GC Europe)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Encapsulated GIC (Equia Fill®, GC Europe)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Occlusoproximal restorations
Number of subjects: 145
Study: 32783178

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy
Number of subjects: 756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 756
Study: 35831719

Group type: EXPERIMENTAL
Intervention: FACT intervention (web-based psychosocial intervention)
Number of subjects: 46